Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VDPHL01 QD
VDPHL01 · 4 trials · 6 indications
Changes from baseline in non-vellus TAHC using digital image analysis at Month 6.
Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 6.
Change from baseline in non-vellus TAHC using digital image analysis at Month 12.
| Arm | Type | Description |
|---|---|---|
| VDPHL01 BID | EXPERIMENTAL | VDPHL01 will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will continue VDPHL01 BID for an additional 6 months. |
| VDPHL01 QD and Placebo QD | EXPERIMENTAL | Placebo will be taken orally once a day (QD) in the AM or PM. VDPHL01 will be taken orally once a day (QD) in the AM or PM for the first 6 months of the study. After month 6, subject will continue this same dose regimen for an additional 6 months. |
| Placebo BID with treatment extension to VDPHL01 BID | PLACEBO_COMPARATOR | Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 BID group, and take VDPHL01 orally twice a day (BID), once in the AM and once in the PM for an additional 6 months. |
| Placebo BID with treatment extension to VDPHL01 QD and Placebo QD | PLACEBO_COMPARATOR | Placebo will be taken orally twice a day (BID), once in the AM and once in the PM for the first 6 months of the study. After month 6, subject will switch to VDPHL01 QD and Placebo QD group, and take placebo orally once a day in the AM or PM; VDPHL01 will be taken orally once a day in the AM or PM for an additional 6 months. |
| VDHPL01 BID | EXPERIMENTAL | VDPHL01 will be taken orally twice a day, once in the AM and once in the PM. |
| VDPHL01 Tablet | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VDPHL01 QD | DRUG | VDPHL01 Extended Release (ER) Tablet |
| Placebo | DRUG | Placebo tablet |
| VDPHL01 BID | DRUG | VDPHL01 Extended Release (ER) Tablet |
| VDPHL01 | DRUG | VDPHL01 Extended Release (ER) Tablet |
Inclusion Criteria: * Subject is a female aged 18-65 years old; * Subject has a clinical diagnosis of mild to moderate AGA; * Subject is in good general health and has adequate renal and hepatic function; * Subject is willing to maintain at least 1/4 inch length hair during the study with the same ...
VDPHL01 is an investigational small molecule in Phase 3 clinical development for androgenetic alopecia, also known as AGA or pattern hair loss. It is being developed by Veradermics, Incorporated, which trades under the ticker MANE. VDPHL01 is a hair growth agent that targets minoxidil, and it is also referred to as VDPHL01 QD.
VDPHL01 is being studied for the treatment of androgenetic alopecia, a form of hair loss affecting both men and women. The clinical program includes separate Phase 3 trials in females and males, plus earlier Phase 2 studies in male and mixed male and female populations. VDPHL01 has not been approved for any use.
VDPHL01 targets minoxidil and belongs to the hair growth agent class. Minoxidil is a well established hair growth compound, and VDPHL01 is designed as a small molecule directed at that target. Its clinical program is evaluating whether this approach improves outcomes in androgenetic alopecia.
VDPHL01 is being developed by Veradermics, Incorporated, a company that trades under the ticker MANE. Veradermics is running the clinical program for VDPHL01 across Phase 2 and Phase 3 studies in androgenetic alopecia, including separate trials for male and female patients.
VDPHL01 is in Phase 3 clinical development for androgenetic alopecia. Two Phase 3 trials are active, one in females and one in males, alongside two earlier Phase 2 studies. VDPHL01 is investigational and has not been approved by the FDA for any indication.
VDPHL01 is being studied in four active trials. The Phase 3 studies are NCT07146022 in females and NCT06972264 in males. The Phase 2 studies are NCT06724614 in males and NCT06527365 in males and females. All four are randomized, double blind, placebo controlled, and conducted in the United States.
Yes, VDPHL01 QD is an alternative name for VDPHL01. Both names refer to the same investigational small molecule being developed by Veradermics, Incorporated for androgenetic alopecia. The QD designation reflects once daily dosing, and searches for either name point to the same drug candidate.